CPT 0115U: ePlex Respiratory Pathogen Panel, 20-Target Multiplex

CPT code 0115U denotes a Proprietary Laboratory Analyses (PLA) test for the ePlex® Respiratory Pathogen (RP) Panel from GenMark Diagnostics, an automated multiplex nucleic acid assay that identifies 20 common respiratory pathogens from nasopharyngeal specimens. As a PLA code, 0115U is specific to one manufacturer’s assay and is used to report that unique test across billing systems. Nationally, molecular respiratory panels like this are important for pathogen identification, infection control, and clinical decision-making, particularly during respiratory virus seasons and outbreaks.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose and service setting for 0115U, plus an outline of common coverage considerations and benchmarks where available. The publication summarizes payer coverage patterns, coding guidance for laboratory reporting, and clinical context for use of multiplex respiratory testing. Data not available in the input is noted where applicable, such as payer-specific reimbursement rates, associated taxonomies, and ICD-10 diagnosis mappings.

Billing Code Overview

CPT code 0115U is a Proprietary Laboratory Analyses (PLA) code for the ePlex® Respiratory Pathogen (RP) Panel (ePlex RP® panel) from GenMark Diagnostics, Inc. The test is an automated molecular multiplexed nucleic acid diagnostic performed on a nasopharyngeal specimen to detect a total of 20 common respiratory pathogens (18 viral and 2 bacterial) in patients suspected of respiratory tract infections.

Service type: Automated molecular multiplex nucleic acid diagnostic testing.

Typical site of service: Clinical laboratory or hospital laboratory that performs high-complexity molecular testing on nasopharyngeal specimens.

Clinical Context

A symptomatic adult or pediatric patient presents to an outpatient clinic, urgent care, emergency department, or hospital with acute respiratory symptoms such as fever, cough, nasal congestion, sore throat, dyspnea, or hypoxia. The clinician suspects a viral or bacterial respiratory infection and orders a multiplex nucleic acid amplification test to identify common respiratory pathogens rapidly. A nasopharyngeal swab is collected per facility infection-control procedures and sent to the laboratory. The laboratory performs the GenMark Diagnostics ePlex® Respiratory Pathogen (RP) Panel, reported with CPT code 0115U, which simultaneously detects 18 viral and 2 bacterial targets. Results are returned to the ordering clinician to inform infection-control decisions, antiviral or antibiotic selection, cohorting, and disposition (discharge, admission, or isolation). Typical sites of service include outpatient clinics, urgent care centers, emergency departments, and inpatient hospital laboratories. Patient scenarios include seasonal influenza-like illness, suspected COVID-19 with atypical presentation, bronchiolitis in infants, or immunocompromised patients with unexplained respiratory symptoms where comprehensive pathogen identification affects management and isolation precautions.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier required / default	General reporting when no special circumstance modifier applies

Taxonomy Code	Specialty	Notes
207Q00000X	Clinical Laboratory	Clinical laboratory directors and staff performing or overseeing molecular diagnostic testing
208000000X	Pathology	Pathologists who review molecular test results and provide interpretations when applicable
363L00000X	Infectious Disease	Infectious disease specialists who order and interpret comprehensive respiratory panels for complex patients
261QM0800X	Pulmonary Disease	Pulmonologists who evaluate patients with acute or chronic respiratory illness and utilize multiplex testing
207LP2900X	Laboratory Technician/Technologist	Medical laboratory technologists who perform the ePlex RP assay in the lab

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J00`	Acute nasopharyngitis (common cold)	Presents with upper respiratory symptoms prompting multiplex testing to identify viral causes
`J06.9`	Acute upper respiratory infection, unspecified	Broad presenting complaint where a respiratory pathogen panel helps identify etiologic agents
`J10.1`	Influenza due to other identified influenza virus with other respiratory manifestations	Panel detects influenza viruses to guide antiviral therapy and infection control
`J12.89`	Other viral pneumonia	Molecular panel assists in identifying viral causes of pneumonia to tailor management
`J21.0`	Acute bronchiolitis due to respiratory syncytial virus	RSV is a target on multiplex panels; identification supports cohorting and treatment decisions in infants
`J98.8`	Other respiratory disorders	Used for atypical or undifferentiated respiratory illness where panel testing may clarify diagnosis
`B97.2`	Coronavirus as the cause of diseases classified elsewhere (historic coding for coronaviruses)	Relevant for coronavirus detection historically and in differential when specific viral targets are sought
`Z03.818`	Encounter for observation for suspected exposure to other biological agents ruled out	Applied when a patient is observed for possible infectious exposure and multiplex testing is performed to rule in/out pathogens

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87070`	Culture, bacterial, any source; with isolation and presumptive identification of isolates	May be ordered alongside molecular panel when bacterial culture confirmation or antimicrobial susceptibility testing is needed for bacterial pathogens identified by the panel
`87428`	Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, amplified probe technique	May be ordered separately or reflexed in workflows during high-sensitivity influenza confirmation or for platforms not detecting all subtypes
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique	May be ordered in parallel or reflex to confirm SARS-CoV-2 when institution policy requires dedicated SARS-CoV-2 testing or for cycle threshold reporting workflows
`87804`	Infectious agent antigen detection by immunoassay, multiple step method, qualitative or semi-quantitative; respiratory syncytial virus (RSV)	Rapid antigen tests may be used at point-of-care with the ePlex panel providing comprehensive confirmation and additional targets
`99000`	Handling and/or conveyance of specimen for transfer from one laboratory to another	Applicable when specimen is sent to a reference lab that performs the proprietary PLA test

OpenPayer

Summary & Overview